- Home
- PMAX vs PPBT Comparison
PMAX vs PPBT Comparison
Compare PMAX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- PPBT
- Stock Information
- Founded
- PMAX 2019
- PPBT 2010
- Country
- PMAX Hong Kong
- PPBT Israel
- Employees
- PMAX N/A
- PPBT N/A
- Industry
- PMAX
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- PPBT Health Care
- Exchange
- PMAX Nasdaq
- PPBT Nasdaq
- Market Cap
- PMAX 6.6M
- PPBT 7.1M
- IPO Year
- PMAX 2024
- PPBT N/A
- Fundamental
- Price
- PMAX $0.45
- PPBT $2.68
- Analyst Decision
- PMAX
- PPBT Strong Buy
- Analyst Count
- PMAX 0
- PPBT 1
- Target Price
- PMAX N/A
- PPBT $33.00
- AVG Volume (30 Days)
- PMAX 820.9K
- PPBT 10.3K
- Earning Date
- PMAX 04-15-2025
- PPBT 03-10-2025
- Dividend Yield
- PMAX N/A
- PPBT N/A
- EPS Growth
- PMAX N/A
- PPBT N/A
- EPS
- PMAX 0.04
- PPBT N/A
- Revenue
- PMAX $5,970,263.00
- PPBT N/A
- Revenue This Year
- PMAX N/A
- PPBT N/A
- Revenue Next Year
- PMAX N/A
- PPBT N/A
- P/E Ratio
- PMAX $8.96
- PPBT N/A
- Revenue Growth
- PMAX 30.05
- PPBT N/A
- 52 Week Low
- PMAX $0.28
- PPBT $2.00
- 52 Week High
- PMAX $4.70
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- PPBT 42.85
- Support Level
- PMAX N/A
- PPBT $2.64
- Resistance Level
- PMAX N/A
- PPBT $2.93
- Average True Range (ATR)
- PMAX 0.00
- PPBT 0.15
- MACD
- PMAX 0.00
- PPBT 0.01
- Stochastic Oscillator
- PMAX 0.00
- PPBT 10.15
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.